 "Lupin receives US FDA nod for dementia and contraceptive drugs")
Lupin Limited has received US drug regulator’s final approvals for generic versions of Eisai Inc’s Aricept (used for treating dementia) tablet and Warner Chilcott’s Loestrin 24 Fe tablet (an oral contraceptive).
Lupin’s donepezil hydrochloride tablet (23 mg) is indicated for the treatment of dementia of the Alzheimer's type and is the generic equivalent of Aricept tablet, which had US sales of $ 52.3 million, according to IMS MAT June 2015.
Lupin has also received marketing approval for its Blisovi 24 Fe tablet (norethindrone acetate and ethinyl estradiol tablet), a generic version of Loestrin 24 Fe tablet, from the US Food and Drug Administration (US FDA). Loestrin 24 Fe tablet, which is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception, had recorded annual sales of $ 56.8 million in the US, according to IMS data.
Lupin’s donepezil hydrochloride tablet (23 mg) is indicated for the treatment of dementia of the Alzheimer's type and is the generic equivalent of Aricept tablet, which had US sales of $ 52.3 million, according to IMS MAT June 2015.
Lupin has also received marketing approval for its Blisovi 24 Fe tablet (norethindrone acetate and ethinyl estradiol tablet), a generic version of Loestrin 24 Fe tablet, from the US Food and Drug Administration (US FDA). Loestrin 24 Fe tablet, which is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception, had recorded annual sales of $ 56.8 million in the US, according to IMS data.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%